Global pharmaceutical company Lupin Limited has announced a licensing and supply agreement with SteinCares, a prominent specialty healthcare firm in Latin America, for the commercialization of its biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.
Under this collaboration, SteinCares will oversee regulatory submissions, product registration, and commercial distribution of ranibizumab in the region, while Lupin will be responsible for manufacturing the product.
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment designed to inhibit vascular endothelial growth factor A (VEGF-A). It is used in the treatment of several retinal conditions, including:
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema following Retinal Vein Occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)
- Myopic Choroidal Neovascularization (mCNV)
Commenting on the agreement, Dr. Cyrus Karkaria, President of Biotechnology at Lupin, stated, “This partnership with SteinCares reflects our commitment to bringing innovative and affordable healthcare solutions to the Latin American region. Together, we aim to transform retinal care by expanding access to cutting-edge therapies that can significantly enhance patient outcomes.”
Sebastián Katz, Chief Strategy Officer at SteinCares, added, “Collaborating with Lupin bolsters our biosimilar portfolio and strengthens our leadership in the region. We pride ourselves on being early movers with products from tightly regulated markets, and this alliance is another step forward in delivering high-quality, cost-effective treatments to healthcare systems across Latin America.”
This strategic partnership is expected to boost access to advanced retinal treatments while delivering cost savings to healthcare providers, leveraging both companies’ strengths and market expertise.
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
